LALPATHLABNSEDr. Lal Path Labs Ltd.MinimalNeutral
Announced Mon, 4 May · 22:54 IST

Dr. Vandana Lal  has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

LALPATHLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.2%1-day move
₹1564.00
prior close
₹1569.20
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.2+0.1+0.2+0.2+1.2-1.1+5.8+5.4+1.4+2.0+2.2-2.0+8.1
Up moveDown movePending
AI summary

Dr. Vandana Lal, Promoter and Whole-Time Director of Dr. Lal Path Labs Limited, has submitted a disclosure confirming that she along with other members of the Promoter/Promoter Group/PAC have not created any encumbrance (pledge) over the company's shares during the financial year ended March 31, 2026. The PAC includes (Hony) Brig. Dr. Arvind Lal (Promoter), Dr. Archana Lal Erdmann (Promoter Group), and Mr. Anjaneya Lal (Promoter Group). Additional entities listed as part of the Promoter Group have nil shareholding. The disclosure also clarifies that Doon MRI Private Limited, shown as part of Promoter Group in the 2015 IPO offer document, does not fall under the definition of Promoter Group as per SEBI ICDR Regulations, 2018.

Likely market impact

A nil encumbrance disclosure is positive for investors as it indicates promoters have not pledged their shares, reducing risk of forced selling. This signals a healthy promoter holding structure with no leverage taken against shares.